Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Renewed investor interest in RNA interference (RNAi) is enabling pioneering companies to forge ahead in the clinic. Does this signify a renaissance in RNAi therapy?
The spectacular performance of biopharma companies in the public markets last year has carried over into optimism for early 2014. Will the boom continue?
Ventures focusing on gene therapy, adoptive T-cell therapy, protein homeostasis and the microbiome are among those selected by the editors in 2013's crop of startups.
Yeast-two hybrid screening of E. coli proteins and integration with protein structure and genetic interaction data provides an extensive interactome resource.
Haplotyping of human genomes is improved by augmenting experimental dilution-based haplotyping with statistical analyses, a strategy known until now only as 'Moleculo.'